video

Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, Morie Gertz, MD, MACP, Mayo Clinic College of Medicine, Rochester, MN, and Raymond Comenzo MD, Tufts University School of Medicine, Boston, MA, discuss the current treatment approach to amyloidosis. They explain the importance of accurate diagnosis, the necessity of determining the amyloid precursor protein, and […]

This short educational video is for patients & caregivers. It is meant to promote better understanding of a rare, under-diagnosed condition called amyloidosis. The hope is to encourage early & precise diagnosis, improved treatments, and positive outcomes.

Professor Sir Dr. Mark Pepys explains diagnosis and treatment of Amyloidosis, links with Alzheimer’s disease and misconceptions about Amyloidosis and Alzheimer’s disease. Prof. Pepys also discusses dementia, inflammation, heart disease and C-reactive Protein (CRP).

This short educational video is for patients & caregivers. It is meant to promote better understanding of a rare, under-diagnosed condition called amyloidosis. The hope is to encourage early & precise diagnosis, improved treatments, and positive outcomes.

Light-chain (AL) amyloidosis is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. The disease often is difficult to recognize because of its broad range of manifestations and what often are vague symptoms.

Mayo Clinic hematologist Angela Dispenzieri, MD, discusses AL amyloidosis treatment including high-dose chemotherapy with stem cell transplantation. Treatment of AL amyloidosis is done through a combination of chemotherapy drugs or by means of stem cell transplant. There are many different types of amyloid medications, and it is important to work with a specialist to establish

Big topics for discussion at this year’s ISA meeting include measurable residual disease (MRD) assessment and hematological response measurement in AL amyloidosis. Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, discusses these hot topics from ISA 2020.

Cousins James and Pat recall the story of their family’s experience of hATTR amyloidosis, including genetic testing and their hopes for the future of those diagnosed with the disease.

Eli Muchtar, MD, Mayo Clinic, Rochester, MN, comments on the potential of artificial intelligence (AI) in predicting the risk of developing AL amyloidosis in patients with multiple myeloma precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). This interview took place at the 2022 International Symposium on Amyloidosis (ISA)

The Amrita Amyloid Centre, the first of its kind in India, provides comprehensive care for amyloidosis patients. It has an expert team specializing in evaluating and treating different types of the disease, such as ATTR, AL, AA, and rare variants. The Centre offers state-of-the-art facilities and a supportive environment for patients and their families.